EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vertex Pharmaceuticals's enterprise value is $79,281 Mil.
Vertex Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $4,509 Mil. Therefore, Vertex Pharmaceuticals's EV-to-EBITDA for today is 17.58.
The historical rank and industry rank for Vertex Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
VRTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1099.73 Med: 17.4 Max: 2085.27
Current: 17.58
During the past 13 years, the highest EV-to-EBITDA of Vertex Pharmaceuticals was 2085.27. The lowest was -1099.73. And the median was 17.40.
VRTX's EV-to-EBITDA is ranked worse than 70.66% of 542
companies
in the Biotechnology industry
Industry Median: 3.90
vs VRTX: 17.58
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2023-10-01), Vertex Pharmaceuticals's stock price is $347.74.
Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $12.950. Therefore, Vertex Pharmaceuticals's PE Ratio for today is 26.85.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Vertex Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Vertex Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Vertex Pharmaceuticals Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
EV-to-EBITDA
53.28
34.33
16.96
16.91
14.51
Vertex Pharmaceuticals Quarterly Data
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
EV-to-EBITDA
15.43
15.46
14.51
16.36
17.80
Competitive Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's EV-to-EBITDA falls in comparison to its industry or sector. The grey bar indicates the EV-to-EBITDA's extreme value range as defined by GuruFocus.
Vertex Pharmaceuticals EV-to-EBITDA Calculation
Vertex Pharmaceuticals's EV-to-EBITDA for today is calculated as:
Vertex Pharmaceuticals's current Enterprise Value is $79,281 Mil.
Vertex Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,509 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vertex Pharmaceuticals's PE Ratio for today is calculated as:
Vertex Pharmaceuticals's share price for today is $347.74.
Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Vertex Pharmaceuticals (NAS:VRTX) Business Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
4.76(1.35%) Volume: 880,285 11:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
VRTX has been successfully added to your 
